Physician profile
Lawrence C Greb
NPI 1134134661
$663.24
in general payments reported to CMS, 2019-2025
14 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $26.41 · 2021: $58.51 · 2022: $68.62 · 2023: $19.67 · 2024: $34.80 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $178.58 | 2019-2025 | |
| Abbvie INC. | $101.78 | 2019-2023 | |
| Astellas Pharma US INC | $80.54 | 2019-2025 | Veozah |
| Avion Pharmaceuticals | $56.97 | 2019 | |
| Amgen INC. | $53.69 | 2019-2025 | Evenity |
| Pfizer INC. | $42.67 | 2021-2022 | |
| Therapeuticsmd, INC. | $27.12 | 2019 | |
| Aspira Women'S Health INC | $26.06 | 2019 | |
| Daiichi Sankyo INC. | $23.32 | 2021 | |
| Organon LLC | $16.09 | 2022 | |
| Sumitomo Pharma America, INC. | $15.11 | 2024 | Gemtesa |
| Lupin INC. | $14.90 | 2019 | |
| Merck Sharp & Dohme LLC | $14.67 | 2020 | |
| Abbott Laboratories | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Greb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.